Rockefeller Financial Services Inc. boosted its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 9.0% during the second quarter, Holdings Channel reports. The fund owned 408,379 shares of the biopharmaceutical company’s stock after buying an additional 33,716 shares during the period. Rockefeller Financial Services Inc.’s holdings in Ultragenyx Pharmaceutical were worth $25,365,000 at the end of the most recent reporting period.
Several other institutional investors have also recently bought and sold shares of RARE. BlackRock Inc. boosted its stake in shares of Ultragenyx Pharmaceutical by 102,249.1% in the first quarter. BlackRock Inc. now owns 3,166,680 shares of the biopharmaceutical company’s stock valued at $214,637,000 after buying an additional 3,163,586 shares in the last quarter. Norges Bank bought a new stake in shares of Ultragenyx Pharmaceutical during the fourth quarter valued at $36,717,000. FMR LLC boosted its stake in shares of Ultragenyx Pharmaceutical by 3.9% in the first quarter. FMR LLC now owns 6,110,627 shares of the biopharmaceutical company’s stock valued at $414,178,000 after buying an additional 227,802 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Ultragenyx Pharmaceutical by 5.7% in the first quarter. Vanguard Group Inc. now owns 2,994,938 shares of the biopharmaceutical company’s stock valued at $202,997,000 after buying an additional 161,622 shares in the last quarter. Finally, Bank of Montreal Can boosted its stake in shares of Ultragenyx Pharmaceutical by 8,939.4% in the first quarter. Bank of Montreal Can now owns 101,603 shares of the biopharmaceutical company’s stock valued at $6,887,000 after buying an additional 100,479 shares in the last quarter. Hedge funds and other institutional investors own 95.25% of the company’s stock.
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ RARE) traded up 0.6469% on Tuesday, hitting $66.7188. The stock had a trading volume of 120,729 shares. Ultragenyx Pharmaceutical Inc. has a 52-week low of $49.97 and a 52-week high of $91.35. The company has a 50-day moving average of $59.37 and a 200-day moving average of $68.56. The company’s market cap is $2.82 billion.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings data on Thursday, May 4th. The biopharmaceutical company reported ($1.63) EPS for the quarter, topping analysts’ consensus estimates of ($1.71) by $0.08. During the same quarter in the prior year, the company posted ($1.35) earnings per share. On average, equities analysts anticipate that Ultragenyx Pharmaceutical Inc. will post ($7.02) EPS for the current fiscal year.
RARE has been the subject of several analyst reports. Zacks Investment Research upgraded Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a report on Tuesday. SunTrust Banks, Inc. increased their target price on Ultragenyx Pharmaceutical from $100.00 to $105.00 and gave the company a “buy” rating in a report on Wednesday, April 19th. Canaccord Genuity restated a “buy” rating and set a $100.00 target price on shares of Ultragenyx Pharmaceutical in a report on Thursday, March 23rd. Robert W. Baird restated an “outperform” rating and set a $90.00 target price on shares of Ultragenyx Pharmaceutical in a report on Wednesday, April 19th. Finally, Jefferies Group LLC lowered Ultragenyx Pharmaceutical from a “buy” rating to a “hold” rating and lowered their price target for the company from $109.00 to $66.00 in a research report on Thursday, April 6th. One analyst has rated the stock with a sell rating, eight have given a hold rating and eight have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $85.71.
In related news, VP Theodore Alan Huizenga sold 480 shares of the business’s stock in a transaction that occurred on Friday, May 26th. The shares were sold at an average price of $57.46, for a total value of $27,580.80. Following the completion of the transaction, the vice president now owns 9,366 shares of the company’s stock, valued at $538,170.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 9.20% of the company’s stock.
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.
Want to see what other hedge funds are holding RARE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE).
Receive News & Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
